Colorado PDAB Takes Precedent-Setting Steps That Could Spur Suits

By Luke Zarzecki / February 21, 2024 at 2:44 PM

Colorado’s Prescription Drug Affordability Board voted Friday (Feb. 16) that Amgen’s Enbrel, used to treat various forms of arthritis and psoriasis, is “unaffordable,” and that Gilead Sciences’ Genvoya, a medication for HIV, was “not unaffordable.”


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.